-
The next patient in your exam room is a 25-year-old single woman who has come in for her quarterly contraceptive injection. At her last visit, she tested positive for chlamydia. She was given a prescription to treat the infection and counseled to have her partner come in for treatment as well. When her lab results are returned prior to your present exam, results are positive for chlamydia.
-
One of the final barriers to availability of emergency contraception (EC) has been toppled with the Food and Drug Administration (FDA) approval of nonprescription sales of the EC drug, Plan B. The drug is manufactured by Barr Pharmaceuticals of Pomona, NY, and marketed by its Duramed subsidiary.
-
Your next patient is a 17-year-old female who is seeking contraception for pregnancy prevention. She is not sure if she wants to take the Pill, and says she's leery of wearing a contraceptive patch. What options can you offer her?
-
How much do you know about natural methods of family planning? While such options may be exactly what some women are seeking, many providers don't learn about them during their medical training.
-
Review the following scenario: a patient has used oral contraceptives for 15 years, starting her first pill pack at age 28. Now at age 43, she tells you, "I had three children by 28 when I started using the Pill. I got divorced three years ago, and now I'm remarried. Why can't I get pregnant? It must be the Pill." What is your counseling strategy?
-
While strides have been made in stemming gonorrhea, clinicians are advised to keep the sexually transmitted disease (STD) on the radar screen. Preliminary new data from the Centers for Disease Control and Prevention (CDC) show sharp increases in reported gonorrhea cases since 2000 in seven states: Alaska, California, Hawaii, Nevada, Oregon, Utah, and Washington.
-
A survey was mailed to 500 members of the American College of Obstetricians and Gynecologists presenting a case of symptomatic fibroids. The respondents were asked to choose hysterectomy or a uterus-sparing procedure, 49% responded.
-
Anderson and colleagues from the WHI performed subgroup analyses focusing on how prior hormone therapy use influenced the risk of breast cancer found in the estrogen-progestin trial arm.
-
The Truth About Multivitamins; Statins and Hepatitis C; Preventing Hot
Flashes; FDA News
-
